Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells

Özdemir, İsmail; PAŞAHAN, RAMAZAN; Akkoç, Mitat; yaşar, sedat; Kul Köprülü, Tuğba; YAŞAR, Şeyma; tekin, saban

doi:10.55730/1300-0527.3418

Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells

Ramazan PAŞAHAN, (İnönü Üniversitesi, Tıp Fakültesi, Nöroşirürji Anabilim Dalı, Malatya, Türkiye)

Mitat AKKOÇ, (Malatya Turgut Özal Üniversitesi, Hekimhan Meslek Yüksekokulu, Mülkiyet Koruma ve Güvenlik Bölümü, Malatya, Türkiye)

Şeyma YAŞAR, (İnönü Üniversitesi, Tıp Fakültesi, Biyoistatistik ve Tıbbi Bilişim Anabilim Dalı, Malatya, Türkiye)

Tuğba KUL KÖPRÜLÜ, (Sağlık Bilimleri Üniversitesi, Deneysel Tıp Uygulama ve Araştırma Merkezi, İstanbul, Türkiye)

Şaban TEKİN, (Sağlık Bilimleri Üniversitesi, Deneysel Tıp Uygulama ve Araştırma Merkezi, İstanbul, Türkiye)

Sedat YAŞAR, (İnönü Üniversitesi, Fen Edebiyat Fakültesi, Kimya Bölümü, Malatya, Türkiye)

İsmail ÖZDEMİR (İnönü Üniversitesi, Tıp Fakültesi, Nöroşirürji Anabilim Dalı, Malatya, Türkiye)

Turkish Journal of Chemistry

3 0

Yıl: 2022 Cilt: 46 Sayı: 4 Sayfa Aralığı: 1097 - 1109 Metin Dili: İngilizce DOI: 10.55730/1300-0527.3418 İndeks Tarihi: 06-12-2022

Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells

Öz:

The 2-methylpyridine, 2-diethylaminoethyl, and isopentyl linked a series of symmetric and unsymmetric benzimidazolium salts 2a-e were prepared and used in the synthesis of silver-N-heterocyclic carbene (NHC) complexes (3a-e). The Ru(II)-NHC complexes (4a-h) were synthesized via transmetalation reaction from 3a-e. 4a-h complexes were converted to Ru(II)-NHC.HCl complexes (5a- h) by HCl solution of diethyl ether and characterized by different spectroscopic techniques such as $^1H and ^{13}C$ NMR, LC/MS-Q-TOF, FT-IR, elemental analysis, and melting point detection. We examined the effect of the structural difference of complexes on anticancer activity via different arenes and metal centers. Antiproliferative activity of 5a-h and 3a was tested against human cervix adenocarcinoma (HeLa) and rat glioblastoma (C6) cell lines by ELISA assay. The $IC_{50}$ value of 5b, 5c and 5e complexes exhibited good cytotoxic activity than cisplatin on C6 (14.2 ± 0.5 mM; 16.2 ± 0.4 mM; 24.2 ± 0.7 mM, respectively) and HeLa (11.1 ± 0.5 mM; 13.7 ± 0.3 mM; 22.8 ± 0.8 mM, respectively) cell lines.

Anahtar Kelime: C6 HeLa antiproliferative activity N-heterocyclic carbene ruthenium silver

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Noch EK, Ramakrishna R, Magge R. Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance. World Neurosurg 2018; 116: 505-517. doi: 10.1016/j.wneu.2018.04.022
2. Giakoumettis D, Kritis A, Foroglou N. C6 cell line: the gold standard in glioma research. Hippokratia 2018; 22 (3): 105-112. PMID: 31641331; PMCID: PMC6801124.
3. Ferrari B, Urselli F, Gilodi M, Camuso S, Priori EC et al. New Platinum-Based Prodrug Pt(IV)Ac-POA: Antitumour Effects in Rat C6 Glioblastoma Cells. Neurotox Research 2020; 37 (1): 183-197. doi: 10.1007/s12640-019-00076-0
4. Günther K, Weber G. Analytiker-Taschenbuch. Berlin, Heidelberg, New York: Springer, 1999.
5. Herrmann WA, Elison M, Fischer J, Köcher C, Artus GRJ. Metal Complexes of N-Heterocyclic Carbenes-A New Structural Principle for Catalysts in Homogeneous Catalysis. Angewandte Chemie International Edition 1995; 34 (21); 2371-2374. doi: 10.1002/anie.199523711
6. Peris E, Mata J, Loch JA, Crabtree RH. A Pd complex of a tridentate pincer CNC bis-carbene ligand as a robust homogenous Heck catalystElectronic supplementary information (ESI) available: synthesis details and NMR data. Chemical Communications 2001; 2: 201- 202. doi: 10.1039/B008038L
7. Izquierdo J, Hutson GE, Cohen DT, Scheidt KA. A continuum of progress: applications of N-hetereocyclic carbene catalysis in total synthesis. Angewandte Chemie International Edition 2012; 51 (47): 11686-11698. doi: 10.1002/anie.201203704
8. Cohen DT, Scheidt KA. Cooperative Lewis acid/N-heterocyclic carbene catalysis. Chemical Science 2011; 3 (1); 53-57. doi: 10.1039/ C1SC00621E
9. Velazquez HD, Verpoort F. N-heterocyclic carbene transition metal complexes for catalysis in aqueous media. Chemical Society Reviews 2012; 41 (21): 7032-7060. doi: 10.1039/C2CS35102A
10. Oehninger L, Rubbiani R, Ott I. N-Heterocyclic carbene metal complexes in medicinal chemistry. Dalton Transactions 2013; 42 (10): 3269-3284. doi:10.1039/C2DT32617E
11. Liu W, Gust R. Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. Chemical Society Reviews 2013; 42 (2): 755- 773. doi: 10.1039/C2CS35314H
12. Gautier A, Cisnetti F. Advances in metal-carbene complexes as potent anti-cancer agents. Metallomics 2012; 4 (1): 23-32. doi: 10.1039/ C1MT00123J
13. Lin JCY, Huang RTW, Lee CS, Bhattacharyya A, Hwang WS et al. Coinage metal-N-heterocyclic carbene complexes. Chemical Reviews 2009; 109 (8): 3561-3598. doi: 10.1021/cr8005153
14. Mercs L, Albrecht M. Beyond catalysis: N-heterocyclic carbene complexes as components for medicinal, luminescent, and functional materials applications. Chemical Society Reviews 2010; 39 (6): 1903-1912. doi: 10.1039/B902238B
15. Yaşar Ş, Köprülü TK, Tekin Ş, Yaşar S. Sulfonated N heterocyclic carbine silver (I) complexes: Synthesis, characterisation, and biological evaluation. Applied Organometalic Chemistry 2018; 32: e4016. doi: 10.1002/aoc.4016
16. Akkoç M, Balcıoğlu S, Canbolat G, Tuğba TT, Burhan A et al. Protonated water-soluble N-heterocyclic carbene ruthenium(II) complexes: Synthesis, cytotoxic and DNA binding properties and molecular docking study. Journal of Organometallic Chemistry 2018; 869: 67-74. doi: 10.1016/j.jorganchem.2018.06.003
17. Hindi KM, Siciliano TJ, Durmus S, Panzner MJ, Medvetz DA et al. Synthesis and anticancer properties of gold(I) and silver(I) N-heterocyclic carbenecomplexes. Journal of Medicinal Chemistry 2008; 51: 1577. doi: 10.1016/j.jorganchem.2010.10.054
18. Patil S, Claffey J, Deally A, Hogan M, Gleeson B et al. Synthesis, Cytotoxicity and Antibacterial Studies of p Methoxybenzyl Substituted and Benzyl Substituted N Heterocyclic Carbene-Silver Complexes. European Journal of Inorganic Chemistry 2010; 1020-1031. doi: 10.1002/ejic.200900889
19. Patil S, Deally A, Gleeson B, Hackenberg F, Muller-Bunz H et al. Pd(II) and trinuclear Ag(I) bis-N-heterocyclic carbene complexes: Synthesis, structural and in vitro anticancer activity. European Journal of Chemistry 2016; 7 (1): 115.doi: 10.5155/eurjchem.7.1.115-120.1387
20. Patil S, Deally A, Gleeson B, Muller-Bunz H, Paradisi F et al. Novel benzyl-substituted N-heterocyclic carbene-silver acetate complexes: synthesis, cytotoxicity and antibacterial studies. Metallomics 2011; 3: 74. doi: 10.1039/c0mt00034e
21. Kantchev EAB, O’Brien CJ, Organ MG. Palladium Complexes of N Heterocyclic Carbenes as Catalysts for Cross Coupling Reactions-A Synthetic Chemist’s Perspective. Angewandte Chemie International Edition 2007; 46: 2768. doi: 10.1002/anie.200601663
22. Barnard PJ, Baker MV, Berners-Price SJ, Skelton BW, White AH. Dinuclear gold(i) complexes of bridging bidentate carbene ligands: synthesis, structure and spectroscopic characterisation. Dalton Transactions 2004; 1038. doi: 10.1039/B316804B
23. Kunz PC, Wetzel C, Kogel S, Kassack MU, Spingler B. [(C3H4N2)2Au]Cl-a bis protic gold(i)-NHC. Dalton Transactions 2011; 40: 35. doi: 10.1039/C0DT01089H
24. Fre ́mont P, Stevens ED, Eelman MD, Fogg DE, Nolan SP. Synthesis and characterization of gold(I) N-heterocyclic carbene complexes bearing biologically compatible moieties. Organometallics 2006; 25: 5824. doi: 10.1021/om060733d
25. Weaver J, Gaillard S, Toye C, Macpherson S, Nolan SP et al. A. Cytotoxicity of Gold(I) N Heterocyclic Carbene Complexes Assessed by Using Human Tumor Cell Lines. Chemisty A European Journal 2011; 17: 6620. doi: 10.1002/chem.201100321
26. Rubbiani R, Kitanovic I, Alborzinia H, Can S, Kitanovic A et al. Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties. Journal of Medicinal Chemistry 2010; 53: 8608. doi: 10.1021/jm100801e
27. Krishnamurthy D, Karver MR, Fiorillo E, Orru V, Stanford SM et al. Gold(I)-Mediated Inhibition of Protein Tyrosine Phosphatases: A Detailed in Vitro and Cellular Study. Journal of Medicinal Chemistry 2008; 51: 4790. doi: 10.1021/jm800101w
28. Berners-Price SJ, Filipovska A. Gold compounds as therapeutic agents for human diseases. Metallomics 2011; 3: 863.doi: 10.1039/c1mt00062d
29. Che C-M, Sun RW-Y. Therapeutic applications of gold complexes: lipophilic gold(III) cations and gold(I) complexes for anti-cancer treatment. Chemical Communications 2011; 47: 9554. doi: 10.1039/C1CC10860C
30. Sutton BM, McGusty E, Waltz DT, DiMartino MJ. Oral gold. Antiarthritic properties of alkylphosphinegold coordination complexes. Journal of Medicinal Chemistry 1972; 15: 1095. doi: 10.1021/jm00281a001
31. Urig S, Fritz-Wolf K, Re ́au R, Herold-Mende C, To ́th K et al. Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases. Angewandte Chemie International Edition 2006; 45: 1881. doi: 10.1002/anie.200502756
32. Rubbiani R, Can S, Kitanovic I, Alborzinia H, Stefanopoulou M et al. Comparative in vitro evaluation of N-heterocyclic carbene gold(I) complexes of the benzimidazolylidene type. Journal of Medicinal Chemistry 2011; 54: 8646. doi: 10.1021/jm201220n
33. Liu W, Bensdorf K, Proetto M, Hagenbach A, Abram U et al. Synthesis, Characterization, and in Vitro Studies of Bis[1,3-diethyl-4,5- diarylimidazol-2-ylidene]gold(I/III) Complexes. Journal of Medicinal Chemistry 2012; 55: 3713. doi: 10.1021/jm3000196
34. Marzano C, Pellei M, Tisato F, Santini C. Copper complexes as anticancer agents. Anti-Cancer Agents Medicinal Chemistry 2009; 9: 185. doi: 10.2174/187152009787313837
35. Barcelo ́-Oliver M, Garcı ́a-Raso A, Terro ́n A, Molins E, Prieto NJ et al. Synthesis and mass spectroscopy kinetics of a novel ternary copper(II) complex with cytotoxic activity against cancer cells. Journal of Inorganic Biochemistry 2007; 101: 649. doi: 10.1016/j. jinorgbio.2006.12.008
36. Pitie ́ M, Donnadieu B, Meunier B. Preparation of the new bis(phenanthroline) ligand “Clip-Phen” and evaluation of the nuclease activity of the corresponding copper complex. Inorganic Chemistry 1998; 37: 3486-3489. doi: 10.1021/ic980044x
37. Suresh D, Balakrishna MS, Rathinasamy K, Panda D, Mague JT. Large-bite bis(phosphite) ligand containing mesocyclic thioether moieties: synthesis, reactivity, group 11 (CuI, AuI) metal complexes and anticancer activity studies on a human cervical cancer (HeLa) cell line. Dalton Transactions 2008; 2285. doi: 10.1039/B719904J
38. Ehrenfeld GM, Shipley JB, Heimbrook DC, Sugiyama H, Long EC et al. Copper-dependent cleavage of DNA by bleomycin. Biochemistry 1987; 26: 931. doi: 10.1021/bi00377a038
39. Teyssot M-L, Jarrousse A-S, Chevry A, De HA, Beaudoin C et al. Toxicity of copper(I)-NHC complexes against human tumor cells: induction of cell cycle arrest, apoptosis, and DNA cleavage. Chemistry A European Journal 2009; 15: 314. doi: 10.1002/chem.200801992
40. Skander M, Retailleau P, Bourrie ́ B, Schio L, Mailliet P et al. N-Heterocyclic carbene-amine Pt(II) complexes, a new chemical space for the development of platinum-based anticancer drugs. Journal of Medicinal Chemstry 2010; 53: 2146. doi: 10.1021/jm901693m
41. Wai-Yin Sun R, Lok-Fung Chow A, Li X.-H, Yan JJ, Sin-Yin Chui S et al. Luminescent cyclometalated platinum(ii) complexes containing N-heterocyclic carbene ligands with potent in vitro and in vivo anti-cancer properties accumulate in cytoplasmic structures of cancer cells. Chemical Science 2011; 2: 728. doi: 10.1039/C0SC00593B
42. Chardon E, Puleo GL, Dahm G, Guichard G, Laponnaz SB. N-Heterocyclic Carbene-Polyethyleneimine (PEI) Platinum Complexes Inducing Human Cancer Cell Death: Polymer Carrier Impact. International Journal of Molecular Sciences 2011; 47: 5864. doi: 10.3390/ ijms19113472
43. Lemke J, Metzler-Nolte N. Organometallic peptide NHC complexes of Cp∗Rh(III) and arene Ru(II) moieties from l-thiazolylalanine. Journal of Organometallic Chemistry 2011; 696: 1018. doi: 10.1016/j.jorganchem.2010.12.044
44. Eimon PM, Rubinstein AL. The use of in vivo zebrafish assays in drug toxicity screening. Expert Opinion Drug Metabolism&Toxicology 2009; 5: 393. doi: 10.1517/17425250902882128
45. Hindi KM, Panzner, MJ, Tessier CA, Cannon CL, Youngs WJ. The medicinal applications of imidazolium carbene-metal complexes. Chemical Reviews 2009; 109: 3859-3884. doi: 10.1021/cr800500u
46. Lamia B, Khaireddine D, Sulaiman A-AA, Ozdemir I, Yasar S et al. Preparation and characterization of PEPPSI-palladium N-heterocyclic carbene complexes using benzimidazolium salts catalyzed Suzuki-Miyaura cross coupling reaction and their antitumor and antimicrobial activities. Journal of Coordination Chemistry 2019; 72: 516-527. doi: 10.1080/00958972.2019.1572886
47. Touj N, Chakchouk-Mtibaa A, Mansour L, Harrath AH, Al-Tamimi J et al. Synthesis, spectroscopic properties and biological activity of new Cu(I) N-Heterocyclic carbene complexes. Journal of Molecular Structure 2019; 1181: 209-219. doi: 10.1016/j.molstruc.2018.12.093
48. Boubakri L, Al-Ayed AS, Mansour L, Harrath AA, Al-Tamimi J at al, In situ palladium/N-heterocyclic carbene complex catalyzed carbonylative cross-coupling reactions of arylboronic acids with 2-bromopyridine under CO pressure: efficient synthesis of unsymmetrical arylpyridine ketones and their antimicrobial activities. Transition Metal Chemistry 2019; 44: 321-328. doi: 10.1007/s11243-018-00298-9
49. Boubakri L, Al-Ayed AS, Mansour L, Abutaha N, Harrath AH et al. Bioactive NHC-derived palladium complexes: synthesis, catalytic activity for the Suzuki-Miyaura coupling of aryl chlorides and bromides and their antibacterial activities. Journal of Coordination Chemistry 2019; 72 (16): 2688-2704. doi: 10.1080/00958972.2019.1664738
50. Touj N, Al Nasr IS, Koko WS, Khan TA, Özdemir I et al. Anticancer, antimicrobial and antiparasitical activities of copper(I) complexes based on N-heterocyclic carbene (NHC) ligands bearing aryl substituents. Journal of Coordination Chemistry 2020; 73: 2889-2905. doi: 10.1080/00958972.2020.1836359
51. Al Nasr I, Touj N, Koko W, Khan T, Ozdemir I et al. Biological activities of NHC-Pd(II) complexes based on benzimidazolylidene N-heterocyclic carbene (NHC) ligands bearing aryl substituents. Catalysts 2020; 10 (10): 1190. doi: 10.3390/catal10101190
52. Boubakri L, Chakchouk-Mtibaa A, Al-Ayed AS, Mansour L, Abutaha N et al. Ru(II)-N-heterocyclic carbene complexes: synthesis, characterization, transfer hydrogenation reactions and biological determination. RSC Advances 2019; 9 (59): 34406-34420. doi: 10.1039/ C9RA05605J
53. Hopkinson MN, Richhter C, Schedler M, Glarious F. An overview of N-heterocyclic carbenes. Nature 2014; 510: 485-495. doi: 10.1038/ nature13384
54. Hickey JL, Ruhayel RA, Barnard PJ, Baker MV, Berners-Price SJ et al. Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. Journal of the American Chemical Society 2008; 130: 12570-12571. doi: 10.1021/ja804027j
55. Oehninger L, Stefanopoulou M, Alborzinia H, Schur J, Ludewig S et al. Evaluation of arene ruthenium (II) N-heterocyclic carbene complexes as organometallics interacting with thiol and selenol containing biomolecules. Dalton Transactions 2013; 42: 1657-1666. doi: 10.1039/C2DT32319B
56. Ott I, Gust R. Non platinum metal complexes as anti-cancer drugs. ArchPharm 2007; 340: 117-126. doi: 10.1002/ardp.200600151
57. Bergamo A, Sava G. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. Dalton Transactions 2011; 40: 7817-7823. doi: 10.1039/C0DT01816C
58. Çiftci O, Beytur A, Vardi N, Özdemir İ. Evaluation of reproductive toxicity in male rats treated with novel synthesized ruthenium(II) and gold(I)-NHC complexes. Drug Development and Industrial Pharmacy 2012; 38 (1): 40-46. doi: 10.3109/03639045.2011.589853
59. Jakupec MA, Galanski M, Arion WB, Hartinger CG, Keppler BK. Antitumour metal compounds: more than theme and variations. Dalton Transactions 2008; 0: 183. doi: 10.1039/B712656P
60. Meier-Menches SM, Gerner C, Berger W, Hartinger CG, Keppler BK. Structure-activity relationships for ruthenium and osmium anticancer agents-towards clinical development. Chemical Society Reviews 2018; 47: 909. doi: 10.1039/C7CS00332C
61. Gasser G, Ott I, Metzler-Nolte N. Organometallic anticancer compounds. Journal of Medicinal Chemistry 2011; 54; 3. doi: 10.1021/ jm100020w
62. Clarke MJ. Ruthenium metallopharmaceuticals. Coordination Chemistry Reviews 2003; 236: 209. doi: 10.1016/S0010-8545(02)00025-5
63. Motswainyana WM, Ajibade PA. Anticancer activities of mononuclear ruthenium(II) coordination complexes. Advances in Chemistry 2015; 1. doi: 10.1155/2015/859730
64. Mura P, Camalli M, Bindoli A, Sorrentino F, Casini A et al. Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans- [bis(2-amino-5- methylthiazole)tetrachlororuthenate(III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound. Journal of Medicinal Chemisty 2007; 50: 5871-5874. doi: 10.1021/jm0708578
65. Ang WH, Casini A, Sava G, Dyson PJ. Organometallic ruthenium-based antitumor compounds with novel modes of action. Journal of Organometallic Chemistry 2011; 696: 989-998. doi: 10.1016/j.jorganchem.2010.11.009
66. Kunick C, Ott I. Metal complexes as protein kinase inhibitors. Angewandte Chemie International Edition 2010; 49: 5226-5227. doi: 10.1002/anie.201002062
67. Levina A, Mitra A, Lay PA. Recent developments in ruthenium anticancer drugs. Metallomics 2009; 1: 458-470. doi: 10.1039/b904071d
68. Alessio E, Mestroni G, Bergamo A, Sava G. Ruthenium antimetastatic agents. Current Topics in Medicinal Chemistry 2004; 15: 1525-1535. doi: 10.2174/1568026043387421
69. Meier-Menches SM, Gerner C, Berger W, Hartinger CG, Keppler BK. Structure-activity relationships for ruthenium and osmium anticancer agents-towards clinical development. Chemical Society Reviews 2018; 47: 909-928. doi: 10.1039/C7CS00332C
70. Dale LD, Tocher JH, Dyson TM, Edwards DI, Tocher DA. Studies on DNA damage and induction of SOS repair by novel multifunctional bioreducible compounds. II. A metronidazole adduct of a ruthenium-arene compound. Anti-Cancer Drug Design 1992; 7; 3. PMID: 2619867.
71. Hackenberg F, Bunz HM, Smith R, Streciwilk W, Zhu X et al. Novel Ruthenium(II) and Gold(I) NHC Complexes: Synthesis, Characterization, and Evaluation of Their Anticancer Properties. Organometallics 2013; 32: 5551-5560. doi: 10.1021/om400819p
72. Casini A, Gabbiani C, Sorrentino F, Rigobello MP, Bindoli A et al. Indoleamine 2,3-dioxygenase ıs the anticancer target for a novel series of potent naphthoquinone-based ınhibitors. Journal of Medicinal Chemistry 2008; 51: 6773-6781. doi: 10.1021/jm8006678
73. Lemke J, Metzler-Nolte N. The synthesis of ruthenium and rhodium complexes with functionalized N heterocyclic carbenes and their use in solid phase peptide synthesis. European Journal of Inorganic Chemistry 2008; 21: 3359-3366. doi: 10.1002/ejic.200800366
74. Alfaro JM, Prades A, Ramos MD, Peris E, RipollGomez J et al. Biomedical properties of a series of ruthenium-N-heterocyclic carbene complexes based on oxidant activity in vitro and assessment in vivo of biosafety in zebrafish embryos. Zebrafish 2010; 7: 13-21. doi: 10.1089/zeb.2009.0601
75. Liu W, Gust R. Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. Chemical Society Reviews 2013; 42: 755- 773. doi.org/10.1039/C2CS35314H
76. Bergamo A, Sava G. Ruthenium complexes can target determinants of tumour malignancy. Dalton Transactions 2007; 1267-1272. doi: 10.1039/B617769G
77. Lentz F, Drescher A, Lindauer A, Henke M, Hilger RA et al. Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. Anti-Cancer Drugs 2020; 20: 97-103. doi: 10.1097/CAD.0b013e328322fbc5
78. Hartinger CG, Jakupec MA, Zorbas-Seifried S, Groessl M, Egger A et al. KP1019, a new redox-active anticancer agent-preclinical development and results of a clinical phase I study in tumor patients. Chemistry Biodiversity 2008; 5: 2140-2155. doi: 10.1002/ cbdv.200890195
79. Bergamo A, Sava G. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. Dalton Transactions 2011; 40: 7817. doi: 10.1039/C0DT01816C
80. Mangiapia G, Errico GD, Simeone L, Irace C, Radulescu A et al. Ruthenium-based complex nanocarriers for cancer therapy. Biomaterials 2012; 33: 3770. doi: 10.1016/j.biomaterials.2012.01.057
81. Simeone L, Mangiapia G, Vitiello G, Irace C, Colonna A et al. Cholesterol-based nucleolipid-ruthenium complex stabilized by lipid aggregates for antineoplastic therapy. Bioconjugate Chemistry 2012; 23: 758. doi: 10.1021/bc200565v
82. Simpson PV, Schmidt C, Ott I, Bruhn H, Schatzschneider. Synthesis, cellular uptake and biological activity against pathogenic microorganisms and cancer cells of rhodium and iridium n heterocyclic carbene complexes bearing charged substituents. European Journal of Inorganic Chemistry 2013; 5547-5554. doi: 10.1002/ejic.201300820
83. Yuan D, Teng Q, Huynh HV. Template-directed synthesis of palladium(II) sulfonate-NHC complexes and catalytic studies in aqueous mizoroki-heck reactions. Organometallics 2014; 33: 1794. doi: 10.1021/om500140g
84. Baquero EA, Flores JC, Perles J, Gomez-Sal P, De Jesús E. Water-soluble mono- and dimethyl N-heterocyclic carbene platinum(II) complexes: synthesis and reactivity. Organometallics 2014; 33: 5470-5482. doi: 10.1021/om500753v
85. Özdemir I, Yiğit B, Çetinkaya B, Ülkü D, Tahir MN et al. Synthesis of a water-soluble carbene complex and its use as catalyst for the synthesis of 2,3-dimethylfuran. Journal of Organometallic Chemistry 2001; 633: 27. doi: 10.1016/S0022-328X(01)01029-4
86. Shaughnessy KH. Hydrophilic ligands and their application in aqueous-phase metal-catalyzed reactions. Chemical Reviews 2009; 109: 643-710. doi: 10.1021/cr800403r
87. Gandin V, Pellei M, Marinelli M, Arzano CM, Dolmella A et al. Synthesis and in vitro antitumor activity of water soluble sulfonate- and ester-functionalized silver(I) N-heterocyclic carbene complexes. Journal of Inorganic Biochemistry 2013; 129: 135. doi: 10.1016/j. jinorgbio.2013.09.011
88. Huynh HV, Yeo CH, Chew YX. Syntheses, structures, and catalytic activities of hemilabile thioether-functionalized NHC complexes. Organometallics 2010; 29: 1479-1486. doi: 10.1021/om9010966
89. Huynh HV, Chew YX. Synthesis, structural characterization and catalytic activity of a palladium(II) complex bearing a new ditopic thiophene-N-heterocyclic carbene ligand. Inorganic. Chimica Acta 2010; 363: 1979. doi: 10.1016/j.ica.2009.02.035
90. Zhang R, Xu Q, Zhang X, Zhang T, Shi M. Axially chiral C2-symmetric N-heterocyclic carbene (NHC) palladium complexes-catalyzed asymmetric arylation of aldehydes with arylboronic acids. Tetrahedron Asymmetry 2010; 21: 1928. doi: 10.1016/j.tetasy.2010.06.041
91. Page PCB, Buckley BR, Christie SDR, Edgar M, Poulton AM et al. A new paradigm in N-heterocyclic carbenoid ligands. Journal of Organometallic Chemisty 2005; 690: 6210. doi: 10.1016/j.jorganchem.2005.09.015
92. Patil S, Deally A, Hackenberg F, Kaps L, M üller-Bunz H et al. Novel benzyl or 4 cyanobenzyl substituted N heterocyclic (Bromo) (carbene)silver(I) and (Carbene)(chloro)gold(I) complexes: synthesis and preliminary cytotoxicity studies. Helvetica Chimica Acta 2011; 94: 1551. doi: 10.1002/hlca.201100107
93. Panzner MJ, Bilinovich SM, Youngs WJ, Leeper TC. Silvermetallation of hen egg white lysozyme: X-ray crystal structure and NMR studies. Chemical Communications 2011; 47: 12479. doi: 10.1039/C1CC15908A
94. Hackenberg F, Lally G, Müller-Bunz H, Paradisi F, Quaglia D et al. Synthesis and biological evaluation of N-heterocyclic carbene-silver(I) acetate complexes derived from 4,5-ditolyl-imidazole. Inorganic Chimica Acta 2013; 395; 135. doi: 10.1016/j.ica.2012.10.029
95. Yasar S, Karaca EO, Sahin C, Ozdemir I, Sahin O et al. Novel ruthenium(II)–N-heterocyclic carbene complexes synthesis, characterization and catalytic application. Journal of Organometallic Chemistry 2015; 1: 289-290. doi: 10.1016/j.jorganchem.2015.04.012
96. Yasar S, Çekirdek S, Ozdemir I. Synthesis, characterization, and transfer hydrogenation of Ru(II)-N-heterocyclic carbene complexes. Journal of Coordination Chemistry 2014; 67; 1236. doi: 10.1080/00958972.2014.911291
97. Syska H, Herrmann WA, Kühn FE. Water-soluble carbene complexes as catalysts for the hydrogenation of acetophenone under hydrogen pressure. Journal of Organometallic Chemistry 2012; 703: 56-62. doi: 10.1016/j.jorganchem.2012.01.001
98. Harison M, Wang J, Lin IJB. Facile synthesis of silver(I)−carbene complexes. Useful Carbene Transfer Agents. Organometallics 1998; 17: 972. doi: 10.1021/om9709704
99. Wang F, Habtemariam A, Van der Geer EPL, Fernandez R, Melchart M et al. Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity. PNAS 2005; 102 (51): 18269. doi: 10.1073/pnas.0505798102
100. Motswainyana WM, Ajibade PA. Anticancer activities of mononuclear ruthenium(II) coordination complexes. Advances in Chemistry 2015; 859730. doi: 10.1155/2015/859730

APA	PAŞAHAN R, Akkoç M, YAŞAR Ş, Kul Köprülü T, tekin s, yaşar s, Özdemir İ (2022). Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells. , 1097 - 1109. 10.55730/1300-0527.3418
Chicago	PAŞAHAN RAMAZAN,Akkoç Mitat,YAŞAR Şeyma,Kul Köprülü Tuğba,tekin saban,yaşar sedat,Özdemir İsmail Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells. (2022): 1097 - 1109. 10.55730/1300-0527.3418
MLA	PAŞAHAN RAMAZAN,Akkoç Mitat,YAŞAR Şeyma,Kul Köprülü Tuğba,tekin saban,yaşar sedat,Özdemir İsmail Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells. , 2022, ss.1097 - 1109. 10.55730/1300-0527.3418
AMA	PAŞAHAN R,Akkoç M,YAŞAR Ş,Kul Köprülü T,tekin s,yaşar s,Özdemir İ Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells. . 2022; 1097 - 1109. 10.55730/1300-0527.3418
Vancouver	PAŞAHAN R,Akkoç M,YAŞAR Ş,Kul Köprülü T,tekin s,yaşar s,Özdemir İ Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells. . 2022; 1097 - 1109. 10.55730/1300-0527.3418
IEEE	PAŞAHAN R,Akkoç M,YAŞAR Ş,Kul Köprülü T,tekin s,yaşar s,Özdemir İ "Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells." , ss.1097 - 1109, 2022. 10.55730/1300-0527.3418
ISNAD	PAŞAHAN, RAMAZAN vd. "Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells". (2022), 1097-1109. https://doi.org/10.55730/1300-0527.3418

APA	PAŞAHAN R, Akkoç M, YAŞAR Ş, Kul Köprülü T, tekin s, yaşar s, Özdemir İ (2022). Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells. Turkish Journal of Chemistry, 46(4), 1097 - 1109. 10.55730/1300-0527.3418
Chicago	PAŞAHAN RAMAZAN,Akkoç Mitat,YAŞAR Şeyma,Kul Köprülü Tuğba,tekin saban,yaşar sedat,Özdemir İsmail Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells. Turkish Journal of Chemistry 46, no.4 (2022): 1097 - 1109. 10.55730/1300-0527.3418
MLA	PAŞAHAN RAMAZAN,Akkoç Mitat,YAŞAR Şeyma,Kul Köprülü Tuğba,tekin saban,yaşar sedat,Özdemir İsmail Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells. Turkish Journal of Chemistry, vol.46, no.4, 2022, ss.1097 - 1109. 10.55730/1300-0527.3418
AMA	PAŞAHAN R,Akkoç M,YAŞAR Ş,Kul Köprülü T,tekin s,yaşar s,Özdemir İ Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells. Turkish Journal of Chemistry. 2022; 46(4): 1097 - 1109. 10.55730/1300-0527.3418
Vancouver	PAŞAHAN R,Akkoç M,YAŞAR Ş,Kul Köprülü T,tekin s,yaşar s,Özdemir İ Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells. Turkish Journal of Chemistry. 2022; 46(4): 1097 - 1109. 10.55730/1300-0527.3418
IEEE	PAŞAHAN R,Akkoç M,YAŞAR Ş,Kul Köprülü T,tekin s,yaşar s,Özdemir İ "Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells." Turkish Journal of Chemistry, 46, ss.1097 - 1109, 2022. 10.55730/1300-0527.3418
ISNAD	PAŞAHAN, RAMAZAN vd. "Synthesis and investigation of antiproliferative activity of Ru-NHC complexes against C6 and HeLa cancer cells". Turkish Journal of Chemistry 46/4 (2022), 1097-1109. https://doi.org/10.55730/1300-0527.3418